-+ 0.00%
-+ 0.00%
-+ 0.00%

DSV (CPSE:DSV) Stock Faces Q3 Earnings Reality Check On Synergy Delays

Simply Wall St·10/22/2026 01:34:03
语音播报

DSV just dropped its Q3 2026 numbers and the mood around the stock does not quite match the freight reality. Coming into the release, the shares had risen about 15% over the past month and barely moved over the last week, which hinted at cautious optimism already priced in. The report then landed with solid volume and profit delivery, including basic earnings per share of 12.6 DKK and adjusted free cash flow of DKK 6.4b. That mix sets up a sentiment clash between investors focusing on short term volatility and those watching the earnings power being rebuilt underneath.

Impressed by DSV’s solid earnings and cash generation but unsure how much sentiment risk you want to take on a single freight stock? Use this as a reference point and line it up against our list of solid balance sheet and fundamentals stocks (203 results).

Q3 2026 Earnings Summary

  • Total Revenue (Q3 2026 vs Q3 2025): DKK 80,702m vs DKK 71,983m (up roughly 12.1%)
  • Net Income Excl. Extra Items (Q3 2026 vs Q3 2025): DKK 3,006m vs DKK 2,141m (up about 40.4%)
  • Basic EPS (Q3 2026 vs Q3 2025): DKK 12.6 vs DKK 9.08 (up roughly 38.7%)
  • Trailing 12 Month Net Profit Margin (Q3 2026 vs Q3 2025): 2.7% vs 4.3% (margin compressed)

Earnings tell you what DSV reported this quarter, but cash flows show what the business actually generates over time, and that is what many valuation focused investors watch most closely.

Based on DSV's recent cash generation alone, this model suggests the stock could be a striking 48% undervalued.

CPSE:DSV Trailing 12-Month Earnings & Revenue History as at Oct 2026
CPSE:DSV Trailing 12-Month Earnings & Revenue History as at Oct 2026

DSV bull case: Schenker and tech targets on the clock

Optimists argue that DSV is on track to turn Schenker plus new systems into a higher earning logistics platform.

"The ongoing large scale integration of Schenker is expected to drive further synergy realisation, with roughly 45% of the planned DKK 9b already in the run rate and management guiding to complete integration by the end of 2026 and reach the full synergy level in 2027, which directly targets higher EBIT and EPS."

Q3 confirms that plan is intact but slower. 2026 EBIT guidance is tightened to DKK 24 to 25b and at least DKK 4b of synergies are still expected in 2026, yet about DKK 1b of the original synergy pool is now deferred into 2027 with full benefit only in 2028. EPS and free cash flow are progressing, so the earnings engine is rebuilding even if the Schenker timetable stretches.

DSV bear case: Road and cash conversion risks still live

On the risk side, sceptics focus on Road and cash conversion as potential drags on the whole story.

"Road operations are still experiencing network integration and service issues in key European markets, with delivery in full and on time metrics around 89% compared with the historical 93% to 95% range. This is driving extra terminal and express transport costs and could hold back EBIT and net margins if normal service levels do not return as planned."

Management now says quality problems in Road are fixed and extra costs have dropped out, yet Q3 still carried about DKK 200 to 300m of residual drag and groupage volumes remain pressured. Group conversion of roughly 32.6% year to date and DKK 6.4b of adjusted free cash flow show better cash efficiency, although working capital is still described as elevated. The risk has eased but timing slippage and a slower Road volume rebuild mean it has not disappeared.

The price and this Narrative do not agree. → Uncover what this Narrative says DSV is actually worth.

Hunt For Disconnected Earnings Stories

DSV shows that earnings progress and sentiment do not always align in the market. The real opportunity is finding stocks that could be undervalued before sentiment adjusts to their earnings profile.

  • Company 1 - 25% below our estimate - leans into expanded facility capacity to ramp higher value memory assembly and AI-focused testing workloads.
  • Company 2 - 30% below our estimate - expands prosthetics and neuro orthotics offerings while overhauling clinics and consolidating manufacturing for cost savings.
  • Company 3 - 49% below our estimate - builds digital lending and business checking platforms that aim to deepen primary small business banking relationships.

Three companies from the same screener. Open the full list of 190 companies trading below our fair value estimates →